RCKT Rocket Pharmaceuticals, Inc.Stock Price & Overview
$22.72
Charts
Quant Ranking
RCKT Analysis
RCKT News
Latest Headlines
Ratings Summary
People Also Follow
Similar to RCKT
ETFs Holding RCKT
RCKT Company Profile
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.
RCKT Revenue
RCKT Earnings Per Share
Earnings Estimates
Earnings Revisions
Valuation
Profitability
Momentum
Capital Structure
Dividends
RCKT Ownership
RCKT Peers
Risk
Technicals
RCKT Transcripts
Investor Presentations
RCKT SEC Filings
Press Releases
RCKT Income Statement
RCKT Balance Sheet
RCKT Cash Flow Statement
RCKT Long Term Solvency
Discover More
You may be interested in: